Commercial-stage biopharmaceutical company Chiasma Inc. (CHMA) announced Q1 results and has also agreed to merge with Amryt Pharma. After jumping 46% on the merger announcement yesterday, shares of ...

The fallout from FDA’s concerns about the design of Chiasma’s ($CHMA) Phase III program has cost one-third of the company’s employees their jobs. Chiasma, an ...

SPA-agreed trial met primary and all secondary endpoints No new or unexpected safety signals in the Mycapssa treated patients 90% of the patients treated with Mycapssa who completed the 36-week study ...

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail ...

Chiasma Inc., a U.S. privately-held biopharma company, announced today that results from a multicenter Phase III study of the investigational new drug, octreotide capsules, were published online for ...

It took four years for Chiasma to bring its acromegaly pill Mycapssa back from the dead, but in late June, the Needham, Massachusetts-based biopharma did just that, scoring a nod for what's now the ...

NEWTON, Mass. and JERUSALEM, March 16, 2015 /PRNewswire/ -- Chiasma, Inc., a U.S. privately-held biopharma company developing octreotide capsules, its lead product for the orphan condition acromegaly, ...

Chiasma Inc.’s stock fell 63 percent Monday on news that US regulators had rejected the Waltham company’s experimental drug to treat a pituitary gland growth disorder. Chiasma, a 15-year-old company ...

No new or unexpected safety signals in the Mycapssa treated patients 90% of the patients treated with Mycapssa who completed the 36-week study opted to continue into the Open Label Extension Company ...